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IS REPEATED HEPATIC RESECTION JUSTIFIED
FOR MALIGNANCY?
ABSTRACT
Huguet, C., Bona, S., Nordlinger, B., Lagrange, L., Parc, R., Harb, J. and
Benard, F.. (1990) Repeat hepatic resection forprimary and metastatic carcinoma of
the liver. Surgery, Gynecology & Obstetrics: 171:398-402
During the last 15 years, 19 patients underwent repeated hepatic resections for
malignant lesions of the liver. The first hepatic resection had been performed four to
40 months earlier for treatment of hepatocellular carcinoma (nine patients) or
hepatic metastases (ten patients), eight of which were of colorectal origin. Repeat
resection was an extensive hepatectomy in six, a segmentectomy in six and a local
excision in seven. In one patient, three wedge resections and, finally, hepatic
transplantation were subsequently performed after an initial extended right lobec-
tomy. The operative mortality rate was 5.2 per cent. The three year actuarial
survival rate’was 64 per cent after the second resection.
PAPER DISCUSSION
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metastases
Huguet and his colleagues present yet further evidence that liver surgery for
primary or metastatic cancer is not a final surgical treatment modality for patients
with metastatic or primary liver tumors. This manuscript tells us that beneficial
results from repeat resection of these tumors is possible. At a time when many
physicians barely accept that surgery is a treatment alternative for this group of
patients, this paper may have some difficulty in receiving a broad implementation.
Yet, this paper is part of a growing literature supporting the practice of repeat
hepatic resections. This paper as others, finds surprisingly good results of surgical
treatment in this very select patient population111.
Tumor Biology of Repeat Resection of Hepatic Tumors
From a tumor biology perspective, repeat resections of primary and metastatic
cancer to the liver finds a firm basis. It’s well substantiated that hepatocellular
carcinoma may occur as a focal process within the liver. The same carcinogenic
events which lead to the first primary tumor can result in a second or even third
disease focus. In other patients, of course, limited margins of resections combined
with intrahepatic dissemination of cancer through the generous lymphatic channels
of the liver may result in a local recurrence. The wedge excision of a primary liver
tumor or even trisectorectomy as a repeat hepatic resection may result in theHPB INTERNATIONAL 67
surgical removal of a second primary tumor or marginal recurrence and therefore
long term disease free survival.
For colorectal metastases to the liver the biologic rationale for this procedure is
sometimes the same but usually quite different. Occasionally, local recurrences
within the liver parenchyma may result. With modern day radiology and liver
parenchyma dissection technology this unfortunate occurrence should be a thing of
the past.
In the majority of patients with colorectal metastases to the liver (or other
tumors giving off tumor emboli to the portal system) the clinician sees over time the
clinical presentation of occult disease in the liver. All liver resectionists at this point
in time accept the fact that the results of treatment of this disease vary directly as
ones ability to detect occult loci of tumor both within the liver and at other systemic
sites. Of course, the CT scanner in the detection of liver, lung and retroperitoneal
disease has gone a long way to improve the results of treatment. As loci of occult
disease grow out over time the astute clinician will attempt to use repeat resections
to render the patient clinically disease free and capable of long term disease free
survival.
The concept of metastatic inefficiency is extremely important in understanding
the tumor biology rationale in patients with repeat hepatic resections12. Metastatic
inefficiency interprets implantation as an unusual event for tumor emboli present
within "endothelial lined basement membrane intact vascular or lymphatic chan-
nels". Interpreted in an evolutionary perspective this body compartment was
designed to transport white cells, red cells, and platelets. Tumor cells enter at their
own risk. Billions of tumor cells are destroyed by a natural process for one tumor
cell to adhere, implant, grow, persist, and progress as a focus of metastatic disease.
Some basic science investigators have suggested that some tumors may only have
th,e biological equipment to implant at a single site13. The integrin system may
confer an organ specific mechanism of adherences. Even though some tumor cells
lines may be injected systemically, the metastatic process turns out to be a selective
process within liver parenchyma. Only liver metastases develop because of unique
liver specific cell surface receptors on the cancer cells that gain access to the blood
stream.
The phenomenon that requires repeat resection of primary and metastatic liver
tumors occurs only in a small proportion of the total patient population.
Hepatocellular carcinoma is an unusually agressive disease process. Recurrences
within the liver are seen to involve major portal venous or major hepatic venous
structures. Repeat resection is usually not compatible with sufficient viable liver
parenchyma for patient survival following the surgery. It’s the unusual patient that
can undergo a repeat resectionTM. A low grade of tumor biology as demonstrated by
well differentiated or fibrolamallar histology is recorded in a majority of patients
with repeat resections of primary liver tumors. Of course, limited or absent liver
regeneration in patients with cirrhosis further reduces the number of candidates for
repeat resection.
Numerous studies regarding the patterns of surgical treatment failure following
15 18 liver resections for metastatic colorectal cancer have appeared in the literature
As emphasized by these authors, systemic recurrence or combinations of systemic
recurrence plus liver recurrence are seen in the great majority of patients with
recurrent disease following liver resection. Studies reported by Griffith and collea-
gues suggested that one in ten liver resection patients may require a repeat
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Survival Benefits as a Result of Surgical Complete Response
Although Huguet and colleagues call our attention to repeat liver metastases, one
should not forget that disease dissemination to other sites in this patient population
is frequently seen. Synchronous or metachronous lung metastases in patients with
large bowel cancer should be considered for surgical removal19. Long term survivals
after liver resection plus lung resection do occur. If one can achieve a complete
response (CR) by surgery the longevity of the patient is prolonged. If these CR’s
can be achieved with minimal morbidity and mortality and are compatible with a
good quality of life following surgery for metastatic disease, then one can with
confidence continue to prolong survival by inducing a surgical CR through the
resection of metastatic cancer.
This concept is not as well supported in the literature for hepatoma as it is for
colorectal metastases. Large bowel cancer patients made clinically disease free of
liver metastases, lung metastases and suture line or resection site recurrence usually
profit with prolonged survival. Recent clinical studies from our group suggest that
some patients with limited peritoneal seeding who have complete resection plus
intraperitoneal chemotherapy may survive long term2. More follow up is needed in
these patients with peritoneal carcinomatosis. However, in summary it’s safe to say
that reoperative surgery that induces in the patient a complete response results in a
prolongation of survival. Five year disease free survival will occur in a lesser group
of patients.
Chemotherapy to Delay the Appearance or Decrease the Incidence of Systemic
Disease
Recent studies in the United States suggest that combination chemotherapy may be
successful in reducing systemic disease and improving long term survival in patients
with Duke’s C colon cancer21. This patient population is quite similar to patients
who have liver resection for metastatic colorectal cancer. Although controlled
studies are not currently available, one suspects that aggressive chemotherapy
employed early on after liver resection may result in substantial improvements in
survival of patients with resected hepatic metastases. The studies of Hodgson,
Friedland, and Ahmed,
22 et al., and Kemeny, Goldberg, and Beatty, et al, suggest
that the clinical evidence of recurrent hepatic metastases may be diminished by
intraarterial chemotherapy. Further studies with combinations of surgical and
chemical liver cytoreduction are underway.
The mortality of the repeat hepatic resections seems reasonable but it is different
from liver resections for cancer the first time around. Ten of nineteen patients in
this series developed a major complication and two patients had two different
postoperative complications. This emphasizes the need to develop prognostic
indicators in this group of patients. The influence of free interval, multiplicity,
preoperative tumor antigen assays and tumor histology need to be determined for
this patient population. Especially the margin of resection of the first and second
liver resection should be correlated with survival.
Medical Economics of Liver Resection
In an era of increasing austerity in health care the Huguet, et al. manuscript causesHPB INTERNATIONAL 69
us to take notice. Our authors suggest that a proportion of patients who fail one
liver resection can benefit from a second. Meticulous follow up is indeed expensive.
Follow up requires frequent visits to a physician, serial tumor antigen assays and
radiologic studies. Perhaps, at least in some part, the success in these patient
populations depends on the successful use of tumor markers. AFP is a marker for
hepatocellular cancer and CEA, or CA19-9 are markers for colorectal cancers. A
large proportion of patients with liver metastases will have progressively elevating
CEA titers. One suspects that the same is true for recurring hepatoma although the
clinical research supporting this is not readily available. Liver radiology using
ultrasound in Europe or CT scanning in the United States has improved not only
technically but in its wider application. With these follow up patients can be
detected at a resectable stage of disease. By Huguet and coworkers data, these
patients are at risk for recurrent liver tumors that can be resected for up to three
years. We have seen recurrent liver tumors up to six years following the first liver
resection (unpublished data).
We recommend the same follow up schedule for patients with liver metastases as
we do with those with Duke’s B or C colorectal cancer23. The 2,4,6 plan is
employed in order to diagnose early recurrences. CEA assays and a visit to a
healthcare professional is recommended every 2 months for the first postoperative
year. In the second and third postoperative year we see the patients every 4
months. And, in the fourth and fifth years every 6 months. A chest radiograph and
a liver imaging study (either ultrasound or CT) is recommended every six months
for 3 years and then on a yearly basis. Clearly, this approach will lead to an
escalation in the cost of care of these patients but must be recommended if one is to
optimize the care of the patients with large bowel primary and metastatic liver
tumors.
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